Spyre Therapeutics Inc. (SYRE)
Healthcare
Biotechnology
98.30 $
-3.1%
vs. previous close
Closing price · As of: 31. Jul 2026
Spyre Therapeutics Inc. (SYRE) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -169 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -7.3 | -11 | -19 | -25 | -32 | -66 | -76 | -54 | -80 | -100 | -157 | -169 | |
| 0.0 | 0.1 | 0.1 | 0.2 | 0.3 | 0.9 | 1.0 | 1.6 | 1.6 | 0.7 | 0.7 | -8.1 | |
| 0.1 | 0.8 | – | – | – | 5.5 | 6.3 | 8.0 | 7.1 | 26 | 45 | 38 | |
| 0.0 | -1.3 | 1.5 | -0.2 | 7.2 | 7.1 | -2.5 | 1.8 | -5.5 | -5.2 | -4.5 | -5.9 | |
| 0.2 | 0.2 | 0.2 | 0.6 | 0.4 | 1.5 | 4.3 | 0.6 | 0.0 | 0.0 | 0.0 | 0.0 | |
| -0.2 | -4.0 | -12 | -23 | -15 | -1.7 | -7.6 | -23 | 57 | – | -353 | -143 | |
| – | -2.0 | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | -0.5 | -0.4 | 0.0 | 0.0 | – | |
| 5.6 | 42 | 49 | 12 | 57 | 66 | 155 | 1.4 | 43 | 361 | 411 | 309 | |
| -2.0 | 27 | 18 | -35 | 9.6 | -3.2 | 71 | -75 | 19 | 153 | -100 | -3.7 | |
| -7.5 | -11 | -19 | -25 | -33 | -67 | -80 | -54 | -80 | -100 | -157 | -169 |
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.